Sep 22, 2026 7 0
Uploaded by Eden
Favorite
Share
More Options
13
TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer - real-world perspective_Page 1

Open in WPS to view all 13 pages